Obesity
Conditions
Keywords
obesity, behavioral intervention, diet
Brief summary
The purpose of this study is to determine the feasibility of providing incentives to people enrolled in a weight-loss program for dietary self-monitoring and/or interim weight loss.
Detailed description
In this study, community outpatients will participate in an effective, 24-week, low-carbohydrate weight loss program delivered via biweekly group classes. An innovative information technology (IT) solution will collate dietary self-monitoring data (input by patients via a mobile phone dietary application) and weight loss data (input by patients via remote scale). An algorithm will classify participants as achieving adequate or inadequate dietary self-monitoring and weight loss to earn intermittent rewards of varying value in real-time. Participants will be notified of earning rewards via text messaging.
Interventions
Participants will receive intermittent financial incentives for recording their dietary intake on a dietary mobile phone application.
Participants will receive intermittent financial incentives for losing an expected amount of weight based weight obtained weekly.
Participants will receive intermittent financial incentives for recording their dietary intake on a dietary mobile phone application and for losing an expected amount of weight based on weight obtained weekly.
Sponsors
Study design
Eligibility
Inclusion criteria
* desire to lose weight; * agree to attend visits per protocol; * access to telephone and transportation; * English speaking; * able to complete study measures; * smart phone with data and texting plan; * body mass index 30 kg/m2 or greater
Exclusion criteria
* pregnancy, breastfeeding, or lack of birth control if premenopausal * dementia, excessive alcohol use, or psychiatric illness * weight loss \>4.5 kg in month prior to screening * weight \> 380 lb (due to limit of cellular scale) * enrollment in other weight loss program * residing in nursing home or receiving home health care * unable to attend weight loss group at scheduled times * impaired hearing * medication other than metformin, incretin mimetics and incretin enhances for type 2 diabetes * unstable heart disease in 3 months prior to screening * furosemide 40 mg or higher (or equivalent) * chronic kidney disease * 2 or more errors on cognitive screener * blood pressure ≥160/100 mmHg
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Weight Change From Baseline to 24 Weeks | 24 weeks | Measured in pounds |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| no Incentives Participants do not receive financial incentives. | 26 |
| Incentives for Dietary Self-monitoring Participants receive financial incentives for dietary self-monitoring.
incentives for dietary self-monitoring: Participants will receive intermittent financial incentives for recording their dietary intake on a dietary mobile phone application. | 26 |
| Incentives for Interim Weight Loss Participants receive financial incentives for interim weight loss.
incentives for interim weight loss: Participants will receive intermittent financial incentives for losing an expected amount of weight based weight obtained weekly. | 27 |
| Incentives for Both Participants receive incentives for dietary self-monitoring and interim weight loss.
incentives for both: Participants will receive intermittent financial incentives for recording their dietary intake on a dietary mobile phone application and for losing an expected amount of weight based on weight obtained weekly. | 26 |
| Total | 105 |
Baseline characteristics
| Characteristic | Incentives for Dietary Self-monitoring | no Incentives | Incentives for Interim Weight Loss | Incentives for Both | Total |
|---|---|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 6 Participants | 4 Participants | 1 Participants | 2 Participants | 13 Participants |
| Age, Categorical Between 18 and 65 years | 20 Participants | 22 Participants | 26 Participants | 24 Participants | 92 Participants |
| Age, Continuous | 51.27 years STANDARD_DEVIATION 15.46 | 49.65 years STANDARD_DEVIATION 12.73 | 46.44 years STANDARD_DEVIATION 11.15 | 45.92 years STANDARD_DEVIATION 12.84 | 48.3 years STANDARD_DEVIATION 13.12 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 0 Participants | 0 Participants | 2 Participants | 2 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 26 Participants | 26 Participants | 27 Participants | 23 Participants | 102 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 1 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) Asian | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) Black or African American | 6 Participants | 7 Participants | 12 Participants | 8 Participants | 33 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 3 Participants | 2 Participants | 1 Participants | 6 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 19 Participants | 15 Participants | 13 Participants | 17 Participants | 64 Participants |
| Region of Enrollment United States | 26 Participants | 26 Participants | 27 Participants | 26 Participants | 105 Participants |
| Sex: Female, Male Female | 24 Participants | 22 Participants | 21 Participants | 25 Participants | 92 Participants |
| Sex: Female, Male Male | 2 Participants | 4 Participants | 6 Participants | 1 Participants | 13 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 26 | 0 / 26 | 0 / 27 | 0 / 26 |
| other Total, other adverse events | 3 / 26 | 3 / 26 | 5 / 27 | 1 / 26 |
| serious Total, serious adverse events | 1 / 26 | 0 / 26 | 0 / 27 | 0 / 26 |
Outcome results
Weight Change From Baseline to 24 Weeks
Measured in pounds
Time frame: 24 weeks
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| no Incentives | Weight Change From Baseline to 24 Weeks | -8.046 Pounds (lbs.) | Standard Deviation 13.316 |
| Incentives for Dietary Self-monitoring | Weight Change From Baseline to 24 Weeks | -15.496 Pounds (lbs.) | Standard Deviation 15.391 |
| Incentives for Interim Weight Loss | Weight Change From Baseline to 24 Weeks | -12.167 Pounds (lbs.) | Standard Deviation 17.884 |
| Incentives for Both | Weight Change From Baseline to 24 Weeks | -17.696 Pounds (lbs.) | Standard Deviation 10.312 |